Access to water, socio-economic inequality and the environmental crisis come to the surface in a thought-provoking exhibition. The Ecologist is an environmental news and analysis website with a focus ...

AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A ...

But now, analyses of hundreds of teeth from La Brea are painting a vastly different picture of this prehistoric terror, which could weigh up to 600 pounds and sported seven-inch-long canine teeth.

AbbVie will pay up to US$1.2 billion to acquire Gilgamesh’s short-acting psychedelic bretisilocin, highlighting growing industry interest in hallucinogenic drugs for the treatment of psychiatric ...

Gilgamesh Brewing started in 2009 by three brothers and their father in Turner. They opened their first restaurant and pub in 2012 in southeast Salem. From 2019 to 2024, they opened three more ...

NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will ...

AbbVie acquires bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion, enhancing its psychiatric care portfolio. Gilgamesh will spin out a new entity to retain its remaining programs ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AbbVie is making a billion ...

One of Australia's newest operas, Gilgamesh, has been crowned the biggest winner of the 2025 Art Music Awards in a ceremony held in Sydney on 21 August. Other winners include former ABC Classic ...

AbbVie’s (NYSE:ABBV) move to buy New York-based psychedelic drug developer Gilgamesh Pharmaceuticals in a deal worth around $1B, according to Bloomberg News, rallied the psychedelic space on Thursday.